FDA Considers Exclusive License for Cancer Treatment Using Mutants of Human IGFBP-3

Summary

The US FDA is contemplating granting an exclusive license to practice inventions related to using mutants of human IGFBP-3 in treating prostate and breast cancers, following a patent application filed by Actis Biologics Inc. in 2001.